278 related articles for article (PubMed ID: 35693455)
1. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.
Anugwom CM; Leventhal TM; Debes JD
Hepatoma Res; 2022; 8():. PubMed ID: 35693455
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang J; Huang H; Chen R; Lin Y; Ling Q
Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in liver transplant: a case series.
Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
[TBL] [Abstract][Full Text] [Related]
4. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy and transplantation for hepatocellular carcinoma.
Tabrizian P; Abdelrahim M; Schwartz M
J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
[TBL] [Abstract][Full Text] [Related]
6. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
7. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
[TBL] [Abstract][Full Text] [Related]
8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
11. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
Nordness MF; Hamel S; Godfrey CM; Shi C; Johnson DB; Goff LW; O'Dell H; Perri RE; Alexopoulos SP
Am J Transplant; 2020 Mar; 20(3):879-883. PubMed ID: 31550417
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy before liver transplant in unresectable hepatocellular carcinoma: a case report.
Ohm H; Khwaja R; Karachiwala H
J Gastrointest Oncol; 2023 Dec; 14(6):2644-2649. PubMed ID: 38196545
[TBL] [Abstract][Full Text] [Related]
13. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.
Wassmer CH; El Hajji S; Papazarkadas X; Compagnon P; Tabrizian P; Lacotte S; Toso C
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760542
[TBL] [Abstract][Full Text] [Related]
15. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials.
Yu J; Li M; Ren B; Cheng L; Wang X; Ma Z; Yong WP; Chen X; Wang L; Goh BC
Front Pharmacol; 2023; 14():1261575. PubMed ID: 37719852
[TBL] [Abstract][Full Text] [Related]
16. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.
Gao Q; Anwar IJ; Abraham N; Barbas AS
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944927
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.
Lin Z; Lu D; Wei X; Wang J; Xu X
Am J Cancer Res; 2020; 10(4):1085-1102. PubMed ID: 32368387
[TBL] [Abstract][Full Text] [Related]
18. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Yin X; Wu T; Lan Y; Yang W
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
[TBL] [Abstract][Full Text] [Related]
20. An analysis report on the application of immune checkpoint inhibitors after liver transplantation.
Xie M; Dang ZP; Sun XG; Zhang B; Zhang Q; Tian QJ; Cai JZ; Rao W
Ther Adv Chronic Dis; 2022; 13():20406223221099334. PubMed ID: 35620187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]